VisionWave Holdings ( $VWAV) Makes Major Eurosatory Push with Modular Autonomous Systems for Modern Warfare; @VWAVInc

 

 

VisionWave Holdings ( $VWAV) Makes Major Eurosatory Push with Modular Autonomous Systems for Modern Warfare; @VWAVInc

 

 

 

 

Investorideas.com, a top rated investment site for retail Investors following AI and defense stocks, reports on breaking news and trading for VisionWave Holdings, Inc (Nasdaq: VWAV), a developer of autonomous systems and AI-enabled battlefield perception technologies.

 

VisionWave Holdings has made double digit gains on news today, currently trading at $5.85+0.77 (+15.09%).

 

VisionWave Holdings, Inc (Nasdaq: VWAV) announced today announced that it plans to formally exhibit at Eurosatory 2026 in Paris, marking the Company’s first large-scale public presentation of its integrated expeditionary mobility and autonomous systems ecosystem.

Originally planned as a private off-site demonstration program, VisionWave has upgraded its participation to a full public exhibition presence at the entrance hall of Eurosatory following inbound inquiries from prospective international partners and defense organizations.

 

At Eurosatory 2026, VisionWave plans to present an integrated operational ecosystem built around the Company’s VARAN™ autonomous ground platform and supporting autonomous systems architecture, including mobile counter-UAS capability, autonomous resupply, remote weapons integration, and passive battlefield perception technologies.

 

Rather than presenting standalone systems, VisionWave’s focus at Eurosatory will center on a unified expeditionary operating concept designed to simplify deployment, reduce training overhead, minimize logistics burden, and provide field-serviceable autonomous capability for forward operations.

 

Paid News Dissemination on behalf of VWAV 

 

Read this news, featuring VWAV in full at https://www.investorideas.com/news/2026/defense/05281-visionwave-vwav-eurosatory-modular-autonomous-systems.asp

 

The Company’s architecture is designed around several core operational principles:

·         One modular mobility platform supporting multiple mission profiles

·         Common operator experience across integrated autonomous systems

·         Reduced sustainment and deployment complexity

·         Expeditionary field-serviceability without heavy infrastructure

·         Open-system integration for rapid capability expansion

·         Designed to support autonomous operation in degraded and contested environments

 

VisionWave believes this approach addresses a growing requirement among allied defense organizations for deployable autonomous systems capable of scaling operational capability without significantly increasing personnel, training, or sustainment demands.

The Company’s Eurosatory presentation will include elements of its broader autonomous operating ecosystem, including:

·         The VARAN™ modular autonomous ground platform

·         Integrated expeditionary mobility and resupply capability

·         Counter-UAS interoperability and autonomous force-protection concepts

·         Passive battlefield perception and navigation technologies

·         Unified operational control and mission coordination architecture

 

Additional operational demonstrations and program updates will be presented during the exhibition and in private partner briefings.

 

Statement from Douglas Davis, Executive Chairman and CEO

“Modern autonomous systems cannot succeed if they create more complexity than they remove,” said Douglas Davis, Executive Chairman and CEO of VisionWave Holdings. “What we are building is not a collection of disconnected products. We are developing an expeditionary autonomy ecosystem designed to simplify mobility, force protection, resupply, and counter-UAS operations under a unified operational framework.”

 

“Reducing logistics drag, minimizing specialized training requirements, and creating systems that operators can sustain and service in the field are foundational to our approach. Eurosatory will be the first public demonstration of that broader vision.”

 

VisionWave at Eurosatory 2026

Dates: June 15-19, 2026

Location : Paris Nord Villepinte exhibition centre ZAC Paris Nord 2, 93420 Villepinte – France (Halls 4 - 5a - 5b - 6)

Format: Public exhibition, live demonstrations, and technical briefings

Hosted by: Doug Davis, Executive Chairman & CEO, alongside VisionWave senior leadership and program personnel

Private partner briefings: Available by appointment during and surrounding exhibition hours

NDA-based technical sessions available for qualified partners and defense organizations

 

Full news:

https://www.investorideas.com/CO/VWAV/news/2026/05281-visionwave-vwav-varan-autonomy-eurosatory.asp

 

Watch recent VWAV video

https://www.youtube.com/shorts/wr4R7VSy7VM

 

VisionWave Holdings is a Featured Defense stock on Investorideaas.om

https://www.investorideas.com/CO/VWAV/

 

Research more defense stocks at Investorideas stock directory

https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp

 

Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire. Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:  https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com - Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas

https://www.investorideas.com/Advertise/

 

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube @Investorideas

 

 

 

 

 

 

 

 

 

From Private Demo to Prime Spot: Defense Stock VisionWave (Nasdaq: $VWAV) to Unveil VARAN Powered Autonomy Ecosystem at Eurosatory; @VWA

 

 

From Private Demo to Prime Spot:  Defense Stock VisionWave (Nasdaq: $VWAV) to Unveil VARAN Powered Autonomy Ecosystem at Eurosatory; @VWAVInc

 

 

 

 

Investorideas.com, a top rated investment site for retail Investors following AI and defense stocks, reports on breaking news and trading for VisionWave Holdings, Inc. (Nasdaq: VWAV), a developer of autonomous systems and AI-enabled battlefield perception technologies.

 

The stock is trading up on news , currently at $5.46 +0.38 (+7.48%).

 

VisionWave Holdings, Inc (Nasdaq: VWAV) announced today announced that it plans to formally exhibit at Eurosatory 2026 in Paris, marking the Company’s first large-scale public presentation of its integrated expeditionary mobility and autonomous systems ecosystem.

Originally planned as a private off-site demonstration program, VisionWave has upgraded its participation to a full public exhibition presence at the entrance hall of Eurosatory following inbound inquiries from prospective international partners and defense organizations.

 

At Eurosatory 2026, VisionWave plans to present an integrated operational ecosystem built around the Company’s VARAN™ autonomous ground platform and supporting autonomous systems architecture, including mobile counter-UAS capability, autonomous resupply, remote weapons integration, and passive battlefield perception technologies.

 

Rather than presenting standalone systems, VisionWave’s focus at Eurosatory will center on a unified expeditionary operating concept designed to simplify deployment, reduce training overhead, minimize logistics burden, and provide field-serviceable autonomous capability for forward operations.

 

Paid News Dissemination on behalf of VWAV 

 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/VWAV/news/2026/05281-visionwave-vwav-varan-autonomy-eurosatory.asp

 

The Company’s architecture is designed around several core operational principles:

·         One modular mobility platform supporting multiple mission profiles

·         Common operator experience across integrated autonomous systems

·         Reduced sustainment and deployment complexity

·         Expeditionary field-serviceability without heavy infrastructure

·         Open-system integration for rapid capability expansion

 

Designed to support autonomous operation in degraded and contested environments

VisionWave believes this approach addresses a growing requirement among allied defense organizations for deployable autonomous systems capable of scaling operational capability without significantly increasing personnel, training, or sustainment demands.

 

The Company’s Eurosatory presentation will include elements of its broader autonomous operating ecosystem, including:

·         The VARAN™ modular autonomous ground platform

·         Integrated expeditionary mobility and resupply capability

·         Counter-UAS interoperability and autonomous force-protection concepts

·         Passive battlefield perception and navigation technologies

·         Unified operational control and mission coordination architecture

 

Additional operational demonstrations and program updates will be presented during the exhibition and in private partner briefings.

 

Statement from Douglas Davis, Executive Chairman and CEO

“Modern autonomous systems cannot succeed if they create more complexity than they remove,” said Douglas Davis, Executive Chairman and CEO of VisionWave Holdings. “What we are building is not a collection of disconnected products. We are developing an expeditionary autonomy ecosystem designed to simplify mobility, force protection, resupply, and counter-UAS operations under a unified operational framework.”

“Reducing logistics drag, minimizing specialized training requirements, and creating systems that operators can sustain and service in the field are foundational to our approach. Eurosatory will be the first public demonstration of that broader vision.”

 

VisionWave at Eurosatory 2026

Dates: June 15-19, 2026

Location : Paris Nord Villepinte exhibition centre ZAC Paris Nord 2, 93420 Villepinte – France (Halls 4 - 5a - 5b - 6)

Format: Public exhibition, live demonstrations, and technical briefings

Hosted by: Doug Davis, Executive Chairman & CEO, alongside VisionWave senior leadership and program personnel

Private partner briefings: Available by appointment during and surrounding exhibition hours

NDA-based technical sessions available for qualified partners and defense organizations

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, without limitation, statements relating to the Company’s planned participation at Eurosatory 2026, development and demonstration of autonomous systems and technologies, future operational capabilities, integration initiatives, strategic positioning, and business development activities.

These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated. Forward-looking statements are generally identified by words such as “believe,” “may,” “will,” “expect,” “intend,” “plan,” “anticipate,” “designed,” and similar expressions.

Risks and uncertainties include, but are not limited to, product development and testing risks, the risk that demonstrations do not achieve expected technical milestones or operational outcomes, regulatory and export-control requirements (including ITAR and EAR compliance for international exhibitions), defense procurement cycles, the uncertainty of converting pilot programs or exhibition interest into binding procurement contracts, financing and capital availability, competitive pressures, geopolitical conditions, integration and commercialization risks, dependence on key personnel and strategic relationships, and other risks described in the Company’s filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q, and 8-K.

All forward-looking statements speak only as of the date of this release, and VisionWave undertakes no obligation to update them except as required by law.

 

About VisionWave Holdings, Inc.

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a defense and advanced sensing technology company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave's mission is to connect defense innovation with civilian progress through shared core technologies deployed across air, land, and fixed-site environments. The Company’s website is https://www.vwav.inc

 

Contact: investors@vwav.inc

 

Watch recent VWAV video

https://www.youtube.com/shorts/wr4R7VSy7VM

 

VisionWave Holdings is a Featured Defense stock on Investorideaas.om

https://www.investorideas.com/CO/VWAV/

 

Research more defense stocks at Investorideas stock directory

https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp

 

Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire.Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:  https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com - Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas

https://www.investorideas.com/Advertise/

 

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube @Investorideas

 

 

 

 

 

 

 

 

 /

Medical Tech Aethlon Medical ( Nasdaq: $AEMD) Soars as Ebola Stocks Gain Momentum

 

Medical Tech Aethlon Medical ( Nasdaq: $AEMD) Soars as Ebola Stocks Gain Momentum

 

 

(Investorideas.com Newswire) Investorideas.com, a leading investment platform for retail investors reports breaking Medical Tech Stock news for  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

Aethlon Medical, Inc. (Nasdaq: AEMD) is trading at 2.9651+0.5151(+21.02%) as of this report on volume  of over 11.8 Million shares.

A serious Bundibugyo Ebola outbreak in central Africa is escalating quickly, prompting a global health emergency declaration and heightened response efforts. This has boosted interest in companies like Aethlon Medical, whose virus-filtering technology could play a role in treatment, lifting its stock price amid the news.

Other Ebola stocks are seeing big gains as headlines this morning say the outbreak is escalating faster than the response.

Paid News Dissemination of behalf of AEMD

Read this news, featuring AEMD in full atv https://www.investorideas.com/CO/AEMD/news/2026/05271-aethlon-medical-aemd-ebola-stocks-momentum.asp

“SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy”

https://stocktwits.com/news-articles/markets/equity/why-is-sngx-stock-up-today-soligenix-ebola-vaccine/cZggefKReAA

These big stock moves are high-risk and volatile and will change with the headlines.

Aethlon Medical, Inc. (NASDAQ: AEMD) recently announced that it is actively monitoring developments related to the current Bundibugyo Ebola virus outbreak in Democratic Republic of the Congo and Uganda and remains prepared to engage with global healthcare and regulatory authorities regarding the potential investigational use of its Hemopurifier® technology.

Aethlon’s Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived EVs from circulation. During the 2014 Ebola (Zaire strain) outbreak, the Hemopurifier was successfully administered to a critically ill Ugandan physician treated at Frankfurt University Hospital under emergency-use circumstances.

At the time Hemopurifier therapy was initiated, the physician was unconscious and suffering from multiple organ failure requiring mechanical ventilation, vasopressor support and continuous dialysis. Following a single 6.5-hour Hemopurifier treatment, the patient’s viral load reportedly declined from approximately 400,000 Ebola virus copies per milliliter of blood to approximately 1,000 copies per milliliter of blood. The Ebola virus subsequently became undetectable five days following treatment. Testing performed after this treatment indicated that the Hemopurifier  captured Ebola virus during therapy; quantitative estimates reported at the time, were approximately 242 million virions. The patient ultimately made recovered and returned home to Uganda.

Full news

https://www.investorideas.com/CO/AEMD/news/2026/05211-aethlon-medical-aemd-ebola-outbreak-hemopurifier.asp

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

Get News Alerts on Aethlon Medical

Disclaimer/Disclosure: Aethlon Medical, Inc. (AEMD) is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

Research biotech  stocks at Investorideas.com

https://www.investorideas.com/Companies/RenewableEnergy/stock_list.asp

About Investorideas.com – Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Investor Ideas digital advertising and guest posts service :

https://www.investorideas.com/Advertise/

Follow us on X @investorideas @stocknewsbites

Follow us on Facebook https://www.facebook.com/Investorideas

Follow Investorideas and the Exploring Mining Podcast on YouTube https://www.youtube.com/c/Investorideas

Investors stay ahead by signing up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

Join our free Telegram community

https://t.me/+o8DxSAgeNCk2ZGVh

Contact us for more info  

Call 800 665 0411

 

 

 

 

 

Ebola Outbreak Spotlights Aethlon Medical’s (Nasdaq: $AEMD) Advanced Preparedness Technology

 

Ebola Outbreak Spotlights Aethlon Medical’s (Nasdaq: $AEMD) Advanced Preparedness Technology

 

 

 

(Investorideas.com Newswire) Investorideas.com, a leading investment platform for retail investors reports breaking Medical Tech Stock news for  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

 

Aethlon Medical, Inc. (NASDAQ: AEMD) today announced that it is actively monitoring developments related to the current Bundibugyo Ebola virus outbreak in Democratic Republic of the Congo and Uganda and remains prepared to engage with global healthcare and regulatory authorities regarding the potential investigational use of its Hemopurifier® technology.

 

According to recent reports from the World Health Organization (“WHO”) and other public health agencies, the current outbreak has been identified as involving the Bundibugyo strain of Ebola virus, a strain for which we are not aware of any approved treatments beyond supportive care, as of the date of this release. Health authorities continue to express concern regarding cross-border transmission and the potential for broader regional spread. Public health assessments, including regarding potential cross-border transmission, are evolving and subject to change.

 

Paid News Dissemination of behalf of AEMD

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2026/05211-aethlon-medical-aemd-ebola-outbreak-hemopurifier.asp

Aethlon’s Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived EVs from circulation. During the 2014 Ebola (Zaire strain) outbreak, the Hemopurifier was successfully administered to a critically ill Ugandan physician treated at Frankfurt University Hospital under emergency-use circumstances.

At the time Hemopurifier therapy was initiated, the physician was unconscious and suffering from multiple organ failure requiring mechanical ventilation, vasopressor support and continuous dialysis. Following a single 6.5-hour Hemopurifier treatment, the patient’s viral load reportedly declined from approximately 400,000 Ebola virus copies per milliliter of blood to approximately 1,000 copies per milliliter of blood. The Ebola virus subsequently became undetectable five days following treatment. Testing performed after this treatment indicated that the Hemopurifier  captured Ebola virus during therapy; quantitative estimates reported at the time, were approximately 242 million virions. The patient ultimately made recovered and returned home to Uganda.

 

That treatment data was presented at the American Society of Nephrology Annual Meeting on November 14, 2014 by Helmut Geiger, M.D., Chief of Nephrology at Goethe University, Frankfurt University Hospital.

 

In the United States, Hemopurifier therapy has previously been made available for Ebola patients through FDA expanded access emergency-use provisions applicable to life-threatening circumstances where alternative therapies may not be available. In January 2015, the U.S. Food and Drug Administration approved an Investigational Device Exemption (“IDE”) supplement that established a regulatory pathway for the potential investigational use of Hemopurifier therapy in Ebola-infected individuals in the United States, subject to applicable institutional approvals and patient protection procedures.

 

Investigational use of medical technologies such as the Hemopurifier may proceed through physician-directed emergency and compassionate-use procedures subject to applicable hospital and regulatory oversight.

 

“We believe the current Ebola outbreak reinforces the ongoing need for broad-spectrum therapeutic approaches capable of addressing viral threats where approved drug therapies or vaccines may be limited,” stated James B. Frakes, Chief Executive Officer of Aethlon Medical. “While the Hemopurifier remains investigational for Ebola treatment, the prior clinical experience on one patient in Germany demonstrated the potential for rapid viral reduction in a critically ill patient under emergency-use conditions.”

 

The Company stated that it will continue to monitor the evolving Ebola situation and will respond to questions or requests from treating clinicians.

 

About the Hemopurifier®

The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived EVs from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects.

 

The Hemopurifier holds a U.S. Food and Drug Breakthrough Device for:

·         The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and

·         The treatment of life-threatening viruses not addressed with approved therapies.

 

The Hemopurifier is being developed under an open IDE for both indications.

 

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids. For more information visit www.AethlonMedical.com and follow the company on LinkedIn.

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Forward-looking statements in this press release  include but are not limited to statements regarding Aethlon’s active monitoring of developments related to the current Bundibugyo Ebola virus outbreak in the Democratic Republic of the Congo and Uganda; potential engagement and responsiveness to inquiries from treating clinicians and hospitals; potential interactions with global healthcare and regulatory authorities concerning potential investigational use of the Hemopurifier technology; the investigational status of the Hemopurifier for Ebola; references to prior emergency-use and FDA expanded access pathways; and the Company’s development plans, regulatory pathway, and potential applications of the Hemopurifier, including its Breakthrough Device designation and ongoing development under an (IDE for oncology and life‑threatening viral indications. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such include, without limitation, the need for and availability of physician-directed emergency or compassionate-use procedures; the requirement for and timing of applicable hospital and regulatory oversight, including institutional approvals and patient protection procedures; uncertainties inherent in investigational use of medical technologies; device performance, deficiencies, or immediate complications; clinical operations, logistics, and timing (including enrollment and access to eligible patients); the status of alternative therapies or supportive care; and the Company’s development plans, regulatory pathway, and potential applications of the Hemopurifier. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Breakthrough Device designation expedites interaction with FDA but does not represent FDA clearance or approval and does not, by itself, establish safety or effectiveness. The findings described herein are preliminary in nature, have not been peer-reviewed, and may not be replicated in subsequent studies or clinical trials. Additional data would be required to assess safety and effectiveness.

 

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com  

 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com  

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Aethlon Medical, Inc. (AEMD) is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 

 Research biotech stocks at Investorideas.com

https://www.investorideas.com/Companies/RenewableEnergy/stock_list.asp

 

 

 

 

About Investorideas.com – Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Why partner with Investor Ideas? Discover our powerful news, PR, social media, and podcast solutions for crypto stocks at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Why should companies choose Investor Ideas for digital advertising and guest posts?

https://www.investorideas.com/Advertise/

 

Follow us on X @investorideas @stocknewsbites

Follow us on Facebook https://www.facebook.com/Investorideas

Follow Investorideas and the Exploring Mining Podcast on YouTube https://www.youtube.com/c/Investorideas

 

Investors stay ahead by signing up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

Join our free Telegram community

https://t.me/+o8DxSAgeNCk2ZGVh

 

Contact us for more info  

Call 800 665 0411